Müller, Volkmar
Royal Marsden NHS Foundation Trust · University of California, Los Angeles · Peter MacCallum Cancer Centre · Edinburgh Cancer Research · Sarah Cannon · University Medical Center Hamburg-Eppendorf · Vanderbilt University Medical Center
4 papers on CoChatORCID 0000-0003-4231-7906
Most cited papers
- Verified
Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., et al. (2020) · New England Journal of Medicine
HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes
Cited by 1,326
- Verified
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology
HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes
Cited by 230
- Verified
Subcutaneous Administration of Monoclonal Antibodies in Oncology
Jackisch, C., Müller, V., Maintz, C., Hell, S., & Ataseven, B. (2014) · Geburtshilfe und Frauenheilkunde
Monoclonal and Polyclonal Antibodies ResearchHER2/EGFR in Cancer Research
Cited by 90
- Verified
Subcutaneous Trastuzumab for HER2-positive Breast Cancer – Evidence and Practical Experience in 7 German Centers
Jackisch, C., Müller, V., Dall, P., Neumeister, R., Park-Simon, T.-W., Ruf-Dördelmann, A., Seiler, S., Tesch, H., & Ataseven, B. (2015) · Geburtshilfe und Frauenheilkunde
HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes
Cited by 42
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free